Exscientia: Georgy Egorov
Exscientia, an articificial intelligence driven drug discovery company, made Georgy Egorov chief financial officer with immediate appointment.
Andrew Hopkins, the CEO of Exscientia said, “Georgy brings an impressive array of skills and experience, particularly in fund raising, corporate strategy and development.”
Egorov previously worked at CompareEuropeGroup where he served as CFO and board member. He has also spent 20 years working in the financial industry with positions at UBS as managing director, as well as executive director of equity and debt at Goldman Sachs.
Egorov stated, “As one of the pioneers in AI-driven drug discovery, Exscientia has the opportunity to play a pivotal role in changing the way drugs are developed.” He further commented that through his appointment he will aim to contribute to Exscientia’s presence within the life sciences industry.